Robert Zeiser

Robert Zeiser's AcademicInfluence.com Rankings

Robert Zeiser

Physics

#7503

World Rank

#9537

Historical Rank

physics Degrees

Download Badge

Physics

Robert Zeiser's Degrees

PhD Physics University of California, Berkeley
Masters Physics Stanford University

Why Is Robert Zeiser Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert Zeiser's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Origin, fate and dynamics of macrophages at central nervous system interfaces (2016) (722)
Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. (2017) (606)
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. (2006) (488)
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey (2015) (423)
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. (2008) (387)
Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R (2010) (364)
Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. (2011) (358)
Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. (2017) (332)
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. (2010) (310)
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. (2014) (309)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. (2020) (283)
Immunodominance and functional alterations of tumor‐associated antigen‐specific CD8+ T‐cell responses in hepatocellular carcinoma (2014) (272)
Continuous T cell receptor signals maintain a functional regulatory T cell pool. (2014) (248)
In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. (2007) (225)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). (2020) (219)
Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage (2014) (210)
Lack of the purinergic receptor P2X7 results in resistance to contact hypersensitivity (2010) (201)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion (2019) (195)
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation (2019) (194)
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. (2020) (193)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (187)
The Nlrp3 inflammasome regulates acute graft-versus-host disease (2013) (186)
In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. (2008) (169)
Unraveling the role of podocyte turnover in glomerular aging and injury. (2014) (153)
Immune modulatory effects of statins (2018) (152)
Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms (2018) (147)
A potential role for P2X7R in allergic airway inflammation in mice and humans. (2011) (146)
P2X7 receptor signaling in the pathogenesis of smoke-induced lung inflammation and emphysema. (2011) (144)
The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. (2015) (135)
Purinergic Receptor Inhibition Prevents the Development of Smoke-Induced Lung Injury and Emphysema (2010) (122)
Immune modulatory effects of oncogenic KRAS in cancer (2020) (117)
MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota. (2019) (117)
Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. (2011) (106)
Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial (2018) (103)
HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice (2020) (103)
Danger signals activating innate immunity in graft-versus-host disease (2011) (101)
NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword (2020) (100)
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. (2021) (99)
Vaccination of advanced prostate cancer patients with PSCA and PSA peptide‐loaded dendritic cells induces DTH responses that correlate with superior overall survival (2006) (98)
GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. (2015) (96)
Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT (2019) (94)
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. (2007) (91)
Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. (2016) (88)
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. (2016) (88)
Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. (2006) (87)
Purinergic receptor type 6 contributes to airway inflammation and remodeling in experimental allergic airway inflammation. (2011) (86)
Pathogenesis of acute graft‐versus‐host disease: from intestinal microbiota alterations to donor T cell activation (2016) (86)
MiR-146a regulates the TRAF6/TNF-axis in donor T cells during GVHD. (2014) (84)
Impact of Mammalian Target of Rapamycin Inhibition on Lymphoid Homing and Tolerogenic Function of Nanoparticle-Labeled Dendritic Cells following Allogeneic Hematopoietic Cell Transplantation1 (2008) (83)
MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation. (2015) (83)
Acute Graft-versus-Host Disease: Novel Biological Insights. (2016) (82)
Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T‐regulatory cells (2009) (82)
Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100. (2013) (80)
Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. (2019) (77)
MicroRNA-155 Exerts Cell-Specific Antiangiogenic but Proarteriogenic Effects During Adaptive Neovascularization (2015) (77)
Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome (2004) (77)
Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. (2018) (76)
MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT-signaling in dendritic cells after stem cell transplantation (2017) (76)
MicroRNA-100 Suppresses Chronic Vascular Inflammation by Stimulation of Endothelial Autophagy (2017) (75)
Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease. (2011) (73)
Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation (2005) (72)
Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. (2018) (68)
Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy (2008) (68)
Role of naturally arising regulatory T cells in hematopoietic cell transplantation. (2006) (65)
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation (2020) (64)
Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. (2016) (63)
Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? (2016) (61)
5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft (2015) (61)
Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives (2004) (59)
Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies (2004) (59)
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms (2020) (58)
Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy (2020) (58)
Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF–licensed myeloid cells (2018) (55)
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors (2013) (55)
miR-146a Controls Immune Response in the Melanoma Microenvironment. (2018) (54)
Clinical follow‐up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis – a single centre experience (2004) (53)
B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. (2015) (51)
Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD. (2015) (51)
CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. (2010) (50)
Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation1 (2009) (50)
Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels (2012) (48)
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life (2018) (47)
BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. (2014) (47)
Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans (2020) (46)
Regulation of different inflammatory diseases by impacting the mevalonate pathway (2009) (45)
Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression (2017) (45)
B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. (2015) (45)
CXCR4 antagonists suppress small cell lung cancer progression (2016) (45)
CD101 Surface Expression Discriminates Potency Among Murine FoxP3+ Regulatory T Cells1 (2007) (44)
Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function (2020) (44)
Advances in understanding the pathogenesis of graft‐versus‐host disease (2019) (43)
Negative regulation of TGF-β1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1b (2017) (42)
B-cell targeting in chronic graft-versus-host disease. (2018) (41)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) (2018) (41)
Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells. (2016) (39)
The Sphingosine 1-Phosphate Receptor Agonist FTY720 Potently Inhibits Regulatory T Cell Proliferation In Vitro and In Vivo12 (2009) (39)
Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GvHD. (2019) (39)
A Novel Function for P2Y2 in Myeloid Recipient–Derived Cells during Graft-versus-Host Disease (2015) (38)
New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions (2020) (38)
The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior (2017) (36)
Glucagon like peptide-2 for Intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. (2020) (34)
Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD (2019) (33)
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions. (2020) (32)
Silencing of the EPHB3 tumor-suppressor gene in human colorectal cancer through decommissioning of a transcriptional enhancer (2014) (32)
MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors. (2020) (32)
Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. (2019) (32)
Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. (2018) (32)
SNAIL1 combines competitive displacement of ASCL2 and epigenetic mechanisms to rapidly silence the EPHB3 tumor suppressor in colorectal cancer (2015) (31)
Insights into the pathogenesis of GvHD: what mice can teach us about man. (2015) (31)
Clinicians and patients perspectives on follow-up care and eHealth support after allogeneic hematopoietic stem cell transplantation: A mixed-methods contextual analysis as part of the SMILe study. (2020) (30)
The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease (2016) (30)
Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects (2015) (29)
CD101 surface expression discriminates potency among murine FoxP3+ regulatory T cells. (2007) (28)
Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells (2013) (28)
Fatal varicella zoster virus encephalitis in two patients following allogeneic hematopoietic stem cell transplantation (2005) (28)
Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation (2016) (28)
Clinical implications of tumor-intrinsic mechanisms regulating PD-L1 (2019) (27)
High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis (2012) (26)
Unlocking the Potential of Purinergic Signaling in Transplantation (2016) (26)
β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression. (2021) (25)
Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation (2004) (24)
Capillary electrophoresis for chimerism monitoring by PCR amplification of microsatellite markers after allogeneic hematopoietic cell transplantation (2005) (24)
Loss of LSR affects epithelial barrier integrity and tumor xenograft growth of CaCo-2 cells (2016) (24)
Intestinal cryptosporidiosis mimicking acute graft-versus-host disease following matched unrelated hematopoietic stem cell transplantation. (2004) (24)
Human hematopoietic cell transplantation results in generation of donor-derived epithelial cells (2005) (24)
Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia. (2019) (23)
Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis (2014) (23)
Stem cell plasticity (2007) (23)
Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index. (2004) (23)
SNAIL1 employs β‐Catenin‐LEF1 complexes to control colorectal cancer cell invasion and proliferation (2020) (23)
Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study (2020) (23)
The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. (2020) (22)
Activation loop phosphorylation regulates B‐Raf in vivo and transformation by B‐Raf mutants (2016) (21)
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia (2021) (21)
Theory-driven development of a medication adherence intervention delivered by eHealth and transplant team in allogeneic stem cell transplantation: the SMILe implementation science project (2020) (21)
Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. (2020) (21)
Fever supports CD8+ effector T cell responses by promoting mitochondrial translation (2021) (21)
Late cytomegalovirus polyradiculopathy following haploidentical CD34+-selected hematopoietic stem cell transplantation (2004) (20)
Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia (2019) (19)
PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model (2020) (19)
The Hematopoietic Niche in Myeloproliferative Neoplasms (2015) (19)
A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model (2013) (18)
Rap1a deficiency modifies cytokine responses and MAPK-signaling in vitro and impairs the in vivo inflammatory response. (2012) (18)
The role of danger signals and ectonucleotidases in acute graft-versus-host disease. (2016) (18)
Ruxolitinib–ECP combination treatment for refractory severe chronic graft-versus-host disease (2020) (18)
Trametinib (GSK1120212). (2018) (18)
Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect (2020) (18)
Therapeutic activity of multiple common gamma chain cytokine inhibition in acute and chronic GvHD (2014) (17)
Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. (2018) (17)
The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation (2021) (17)
The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia. (2011) (17)
Immunization against poly-N-acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity (2019) (16)
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in adult patients with high-risk or advanced Ewing and soft tissue sarcoma (2006) (16)
The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin’s Lymphoma (2019) (15)
Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect. (2006) (15)
Immunotherapy in Myeloproliferative Diseases (2020) (15)
Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic cell transplantation. (2006) (14)
Immunotherapy for Malignant Melanoma Robert (2012) (14)
Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease. (2007) (14)
The Sphingosine 1-Phosphate Receptor Agonist FTY720 Potently Inhibits Regulatory T Cell Proliferation In Vitro and In Vivo (2009) (14)
An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients (2016) (14)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. (2021) (14)
Graft‐versus‐host disease reduces regulatory T‐cell migration into the tumour tissue (2012) (13)
Metadherin exon 11 skipping variant enhances metastatic spread of ovarian cancer (2015) (13)
Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity (2020) (13)
Reprint of: Acute Graft-versus-Host Disease: Novel Biological Insights. (2016) (12)
Detection of major histocompatibility complex molecules in processed allogeneic bone blocks for use in alveolar ridge reconstruction. (2018) (12)
NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia. (2019) (11)
Acute Graft-versus-Host Disease. (2018) (11)
Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth—the SMILe study (2021) (10)
Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth—the SMILe study (2021) (10)
Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. (2019) (10)
Activation of Innate Immunity in Graft-versus-Host Disease: Implications for Novel Targets? (2015) (10)
Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis (2021) (10)
Premature Terminal Differentiation Protects from Deregulated Lymphocyte Activation by ITK-Syk (2014) (10)
B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model (2019) (10)
Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib (2016) (10)
Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: Case 1. Multiple myeloma relapse presenting as malignant pericardial effusion. (2005) (10)
Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia (2019) (10)
Introduction to a review series on chronic GVHD: from pathogenic B-cell receptor signaling to novel therapeutic targets. (2017) (10)
Biology-driven developments in the therapy of acute graft-versus-host disease. (2018) (9)
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. (2022) (9)
Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality (2019) (9)
Type II HMG-CoA Reductase Inhibitors (Statins) Provide Acute-Graft-Versus-Host Disease Protection by Th-2 Cytokine Induction While Sparing Graft-Versus-Leukemia Activity. (2006) (9)
Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses. (2020) (8)
High‐dimensional single‐cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis (2019) (8)
Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy. (2020) (8)
Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. (2021) (8)
BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib (2014) (8)
Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma. (2020) (8)
P2Y2R Signaling Is Involved in the Onset of Glomerulonephritis (2018) (8)
Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease (2021) (8)
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis (2019) (8)
Inflammasome effects in GvHD (2015) (7)
In Vivo Myeloperoxidase Imaging and Flow Cytometry Analysis of Intestinal Myeloid Cells. (2016) (7)
Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation (2020) (7)
Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model (2016) (7)
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (7)
Early CD 30 signaling is critical for adoptively transferred CD 4 CD 25 regulatory T cells in prevention of acute graft-versus-host disease (2007) (7)
Ectonucleotidases in Solid Organ and Allogeneic Hematopoietic Cell Transplantation (2012) (7)
Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. (2019) (7)
High grade cardiac lymphoma vitality monitoring by gadolinium-enhanced magnetic resonance imaging (MRI). (2005) (6)
Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation (2020) (6)
The death receptor pathway is not involved in alloreactive T-cell induced mitochondrial membrane permeability (2005) (6)
Non-classical manifestations of acute GVHD. (2021) (6)
High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group (2022) (6)
Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation (2016) (6)
Loss of the Fanconi anemia-associated protein NIPA causes bone marrow failure. (2020) (6)
Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDS (2016) (6)
Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. (2022) (5)
Inhibition of Protein Geranylgeranylation and Farnesylation Protects Against GVHD (2011) (5)
Towards a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. (2022) (5)
Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease (2021) (5)
Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. (2021) (5)
Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. (2022) (5)
Cobimetinib (GDC-0973, XL518). (2018) (5)
calcineurin-dependent interleukin-2 production Inhibition of CD4+CD25+ regulatory T-cell function by (2013) (4)
Harnessing GVHD by interleukin-6 receptor blockade. (2014) (4)
Oncogenic KrasG12D Activation in the Nonhematopoietic Bone Marrow Microenvironment Causes Myelodysplastic Syndrome in Mice (2021) (4)
Three FDA-approved therapies for chronic GVHD. (2022) (4)
GVHD, IBD, and primary immunodeficiencies: The gut as a target of immunopathology resulting from impaired immunity (2022) (4)
A delicate balance (2013) (4)
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation (2022) (4)
Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients (2015) (4)
Pregnancy Specific β-1 Glycoprotein 1 is Expressed in Pancreatic Ductal Adenocarcinoma and its Subcellular Localization Correlates with Overall Survival (2016) (4)
Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia (2019) (4)
Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion (2019) (4)
Sorafenib Promotes Graft-Versus-Leukemia Activity in Mice and Humans through IL-15 Production in Leukemia Cells (2016) (4)
Immunotherapy for malignant melanoma. (2012) (4)
Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model (2020) (4)
Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells (2019) (4)
Baricitinib for patients with severe COVID-19—time to change the standard of care? (2022) (4)
The Role of MicroRNAs in Myeloid Cells during Graft-versus-Host Disease (2018) (3)
Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case (2021) (3)
IRE1 and PERK signaling regulates inflammatory responses in a murine model of contact hypersensitivity (2021) (3)
Differential impact of mTOR inhibition on CD4CD25Foxp3 regulatory T cells as compared to conventional CD4 T cells Running title: Impact of mTOR inhibition on Treg and Tconv (2007) (3)
Retinoic acid signaling acts as a rheostat to balance Treg function (2022) (3)
Introduction to a review series on pathophysiology and treatment of acute GVHD (2020) (3)
The impact of pulmonary function in patients undergoing autologous stem cell transplantation (2021) (3)
Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study (2020) (3)
Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma (2020) (3)
Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation (2016) (3)
Allogeneic hematopoietic cell transplantation for t-AML following liver transplantation from the same haploidentical donor (2009) (3)
The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (2019) (3)
NKT Cells Are Potent Regulators of GVHD Following Adoptive Transfer in Allogeneic BMT. (2007) (3)
Response to JAK 1/2 Inhibition in Patients with Corticosteroid-Refractory Acute Graft-Versus-Host Disease (2014) (3)
TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis (2019) (2)
Erratum: Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood. 2016;127(25):3117-3126. (2016) (2)
Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling (2022) (2)
Trial in Progress: Gravitas-301, a Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo with Corticosteroids (CS) for the First-Line Treatment of Patients with Acute Gvhd (aGVHD) (2018) (2)
Age-dependent leiomuscular atrophy in vertebral arteries of individuals under low fat diet. (2000) (2)
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation (2022) (2)
Acute Graft-Versus-Host Disease, Infections, Vascular Events and Drug Toxicities Affecting the Central Nervous System (2021) (2)
PO-33 - Heparin suppresses progression of small cell lung cancer (SCLC) in an orthotopic mouse model. (2016) (2)
Editorial: Non-coding RNAs and Graft versus Host Disease (2018) (2)
Thrombectomy discloses intravascular growth of chondroid liposarcoma mimicking a long distance vena cava thrombosis. (2004) (2)
Prevention of Acute Graft-Versus-Host Disease by CD4+CD25+ Regulatory T Cells Is Dependent on the CD30/CD153 Pathway. (2005) (2)
GVHD-associated , in fl ammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells (2015) (2)
Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy (2021) (2)
Beclin-1 Phosphorylation By BCR-ABL Is Crucial for CML Leukemogenesis By Suppression of Autophagy (2015) (2)
Therapeutic targeting of endoplasmic reticulum stress in acute graft-versus-host disease (2021) (2)
Allogeneic Stem Cell Transplantation - A Long-Term Curative Approach In Patients ≥ 60 Years With Advanced Disease AML/MDS, - The Freiburg Experience Of 250 Consecutive Patients (2013) (1)
Enhanced immune reconstitution and function by CD4+CD25+ regulatory T cells following allogeneic hematopoietic cell transplantation (2006) (1)
Introduction to How I Treat Series on Common Medical Problems after Allogeneic Stem Cell Transplantation. (2020) (1)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report Transplantation and Cellular Therapy (2021) (1)
Introduction to a review series on Biology driven strategies to treat acute GVHD. (2020) (1)
Chemical Mutagenesis Screen Identifies Novel Drug Resistant JAK2 Variants in V617FJAK2 Mediated MPN and Predict HSP90 Inhibitors As Possible Agents to Overcome Drug Resistance (2015) (1)
Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape (2022) (1)
Phase Contrast MR Imaging to Image Bacterial translocation in a Mouse Model for Graft versus Host Disease (2012) (1)
Selective Expansion of Human Regulatory (CD4+CD25+CD127LowFOXP3+) Cells to High Purity by Inhibiting Expansion of CD4+CD25+CD127HighFOXP3-Conventional T Cells with Rapamycin. (2006) (1)
Introduction to a review series on strategies to improve GVL effects. (2018) (1)
Impact of mTOR Inhibition on FoxP3+ Regulatory T Cells as Compared to Conventional T Cells after Allogeneic Bone Marrow Transplantation. (2006) (1)
Recipient Dendritic Cells Are Regulated By MiR-146a during Acute GvHD (2015) (1)
MicroRNA-155 exerts anti-angiogenic but pro-arteriogenic effects in the regulation of adaptive neovascularization in mice by cell specific regulation of divergent target genes (2013) (1)
ATP Acts as Danger Associated Molecular Pattern and Enhances Acute Graft-Versus-Host Disease Severity Via P2×7-R. (2009) (1)
Regulatory T Cells: Broadening Applicability (2018) (1)
Common Gamma Chain Cytokines Contribute To Acute GvHD Via Perforin/Granzyme B-Mediated Cytotoxicity Of CD8 T Cells (2013) (1)
Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (Pts) with Glucocorticoid-Refractory Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study (2021) (1)
PET imaging of inflammatory processes during GvHD (2011) (1)
Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease (2021) (1)
Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation (2022) (1)
[The role of microRNAs for immunoregulation after allogeneic hematopoietic cell transplantation]. (2014) (1)
P2Y6 Receptor Contributes to Airway Inflammation and Remodeling in Experimental Allergic Airway Inflammation (2011) (1)
Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function (2023) (1)
Micro-RNA and Kinase Regulatory Mechanisms and Pathways in GVHD (2019) (1)
In Vivo Effects of Cyclosporine A, Mycophenolate Mofetile and Rapamycin on Adoptively Transferred CD4+CD25+ Regulatory T Cells in Prevention of Experimental Acute Graft-Versus-Host Disease. (2005) (1)
Early Treatment with CD4+CD25+ Regulatory T Cells Provides Prolonged Suppressive Effects Which Control Evolving but Not Established Graft-Versus-Host-Disease. (2005) (1)
Evaluating safety and efficacy of immune checkpoint inhibitors (ICI) in elderly patients (pts) for advanced cancer treatment: A retrospective study (2018) (1)
Siglec-G signaling DAMPens GVHD. (2014) (1)
Deciphering the role of Minor histocompatibility antigens for acute graft-versus-host disease. (2021) (1)
Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use (2022) (0)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) (2018) (0)
allogeneic transplantation effective strategies to control graft-versus-host disease following In vivo dynamics of regulatory T-cell trafficking and survival predict (2013) (0)
Comparison of Conventional Versus Lineage-Specific Chimerism Analysis for Detection of Minimal Residual Disease or Relapse in Myeloid Malignancies after Myeloablative Allogeneic Hematopoietic Cell Transplantation with Respect to Clinical Follow-Up. (2004) (0)
Low-Dose 5-Azacytidine Combined With Donor Lymphocyte Infusions (DLI), An Effective Outpatient Treatment Of AML/MDS Relapse After Allografting, Can Induce Long-Term Remissions: An Experience Of 72 Patients (2013) (0)
S230: HUMAN ΒETA-DEFENSIN 2 TREATMENT MODULATES THE INTESTINAL MICROBIOME AND THE ALLOGENEIC T CELL RESPONSE TO LIMIT ACUTE GRAFT-VERSUS-HOST DISEASE (2022) (0)
Vaccination Against Poly-N-Acetylglucosamine Decreases Neutrophil Activation and Gvhd While Maintaining Microbial Diversity (2019) (0)
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT (2021) (0)
MiR-146a Regulates the TRAF6/TNF-Axis in Donor T Cells during Graft-Versus-Host Disease (2014) (0)
Long-Term Follow-up of Therapy-Related MDS and AML Patients Treated with Allogeneic Hematopoietic Cell Transplantation Reveals Substantial 10 Year Survival and Comparably Low Treatment-Related Mortality (2014) (0)
Introduction to the How I Treat Series on "How I Manage High-Risk Patients Following Allogeneic Transplant". (2022) (0)
Neutrophil Isolation from the Intestines (2015) (0)
Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia (2022) (0)
P1389: RUXOLITINIB DEMONSTRATES A GREATER CORTICOSTEROID-SPARING EFFECT THAN BEST AVAILABLE THERAPY IN PATIENTS WITH CORTICOSTEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VS-HOST DISEASE (2022) (0)
Checkpoint Inhibition in CSF3R Mutated Chronic Neutrophilic Leukemia (2018) (0)
Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse (2022) (0)
Differential Impact of Host Derived Interleukin-18 on Regulatory and Conventional T Cell Expansion Following Murine Allogeneic Hematopoietic Cell Transplantation. (2007) (0)
Tissue-Specific Homing of Natural Killer Cells in Allogeneic Bone Marrow Transplantation. (2006) (0)
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation (2019) (0)
Regulatory T Cell Therapy for Immunomodulation After Allogeneic Hematopoietic Cell Transplantation (2010) (0)
Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309 (2022) (0)
The Fanconi Anemia-Associated Protein NIPA Is Essential for the Nuclear Abundance of FANCD2 (2019) (0)
Effective and Safe Immune Checkpoint Blockade Induces Complete Responses in Murine PTCL Model of ALCL (2022) (0)
An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients (2016) (0)
Contributors (2019) (0)
Immune responses to the microbiome tune MHC class II antigen presentation by the intestinal epithelium to control gut pathology (2019) (0)
graft-versus-leukemia activity disease protection by Th-2 polarization while sparing Preemptive HMG-CoA reductase inhibition provides graft-versus-host (2013) (0)
S861 LOSS OF THE F-BOX PROTEIN NIPA CAUSES BONE MARROW FAILURE (2019) (0)
Enhanced Immune Reconstitution and Function by CD4+CD25+ Regulatory T Cells Following Allogeneic Hematopoietic Cell Transplantation. (2005) (0)
Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease. (2023) (0)
Summary and Outlook on the Future Challenges of Allogeneic HSCT (2019) (0)
Reach-2 Trial Design: A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Compared to Best Available Therapy in Patients with Corticosteroid-Refractory Acute Graft vs Host Disease after Allogeneic Stem Cell Transplantation (2018) (0)
Table 43.2, [Clinical manifestations of acute GvHD]. (2019) (0)
β2-m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation (2019) (0)
Ruxolitinib for Chronic Graft-versus-Host Disease. Reply. (2021) (0)
Study Design of a Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Over BAT in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation (REACH-3) (2018) (0)
Overview of the Immune Biology of Allogeneic HSCT (2019) (0)
TRANSPLANTATION MicroRNA-155 – de ﬁ cient dendritic cells cause less severe GVHD through reduced migration and defective in ﬂ ammasome activation (2015) (0)
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract (2022) (0)
Recipient IL-33 stimulates donor T cells to promote Type 1 alloimmunity and lethal acute GVHD (TRAN1P.931) (2015) (0)
Use of R-spondin1, An Intestinotrophic Mitogen, in the Treatment of Murine Graft-Versus-Host Disease (2008) (0)
39: Differential impact of mTOR inhibition on FoxP3+ regulatory T cells as compared to conventional T cells after allogeneic bone marrow transplantation (2007) (0)
Author Correction: Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function (2020) (0)
Gvhd Severity Is Regulated by the Adoptive Transfer Low Numbers of NKT Cells by a Mechanism Distinct From CD4+CD25+ Regulatory T Cells. (2009) (0)
Nampt Inhibition, ein neuer Therapieansatz bei akuter graft-versus-host-disease. (2020) (0)
in minimal GVHD with retention of antitumor activity In vivo trafficking and survival of cytokine-induced killer cells resulting (2013) (0)
Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model (2019) (0)
Differential effects of immunosuppressants on adoptively transferred CD4+CD25High regulatory T cells in prevention of experimental acute graft-versus-host disease (2006) (0)
High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis (2012) (0)
Response to Letter Regarding Article, "MicroRNA-155 Exerts Cell-Specific Antiangiogenic but Proarteriogenic Effects During Adaptive Neovascularization". (2015) (0)
Adoptive Transfer of NKT Cells Reduces GVHD Severity Via an IFN-γ And IL-4 Dependent Mechanism (2009) (0)
Retraction notice to "Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer" [Canc. Lett. 520 (2021) 385-399]. (2022) (0)
Caveolin-1 Is Required For T Cell-Mediated Acute GvHD (2013) (0)
The Probability of Being in Response (PBR): A Novel Efficacy Endpoint for Chronic Graft Versus Host Disease (GvHD) Applied to the Reach-3 Study of Ruxolitinib Versus BAT (2022) (0)
301: Selective expansion of human regulatory (CD4+CD25+CD127LowFOXP3+) cells to high purity by inhibiting expansion of CD4+CD25+CD127HighFOXP3- conventional T cells with rapamycin (2007) (0)
Effect of the Neddylation Inhibitor Pevonedistat on Normal Hematopoietic Stem Cell Subsets and Immune Cell Composition (2021) (0)
Plenary Sessions (2018) (0)
Prognostic Value of Blood Biomarkers in Steroid-Refractory/Dependent Acute Graft-vs-Host Disease: A REACH2 Analysis. (2023) (0)
The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Organizing Committee (2019) (0)
Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia (2021) (0)
Early treatment with CD4+CD25+ regulatory T cells provides prolonged suppressive effects which control evolving but not established graft-versus-host-disease (2006) (0)
Epigenetic Regulation to Enhance Graft-versus-Leukemia Activity. (2022) (0)
335: Inhibition of HMG-CoA reductase activity with statins provides acute-graft-versus-host disease protection by Th-2 cytokine induction while sparing graft-versus-leukemia activity (2007) (0)
Minimal Residual Disease (MRD) Analysis Using Multiparametric Flow Cytometry (MFC) and Identification of Differences in Subpopulations Using Next Generation Sequencing (NGS) in the Bone Marrow (BM) of Multiple Myeloma (MM) Patients (pts) (2018) (0)
graft-versus-host disease -nucleotidase in mice enhances acute ' Deficiency of CD73/ecto-5 (2013) (0)
FTY720 Abrogates the Therapeutic Potential of Adoptively Transferred Treg Via Inhibition of IL-2 Induced in Vivo Expansion. (2008) (0)
Gram Stain for Intestinal Bacteria (2015) (0)
Ruxolitinib for Acute Graft-versus-Host Disease. Reply. (2020) (0)
Oncogenic KRASG12D in the Hematopoietic System Causes NLRP3 Inflammasome Activation Leading to Myeloproliferative Syndrome (2018) (0)
IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease Following Bone Marrow Transplantation, (2011) (0)
Negative regulation of TGF-β1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1b (2017) (0)
Mo1882 – Immune Cell and Checkpoint Signatures in Pbmc of Patients with Ulcerative Colitis (2019) (0)
Predictive Markers for Acute Graft-Versus-Host Disease in the Peripheral Blood - Surface Receptor Profile Defines Alloreactive T Cells In Vivo . (2006) (0)
Editorial on Translational Research in Graft-Versus-Host Disease (GVHD) and Graft-Versus-Tumor (GVT) Effect After Allogeneic Hematopoietic Cell Transplantation (2022) (0)
Comparison of Gel Versus Capillary Electrophoresis for Chimerism Monitoring by PCR Amplification of Microsatellite Markers after Allogeneic Hematopoietic Cell Transplantation. (2004) (0)
Tumormicroenvironment (2021) (0)
IL-33 mediated expansion of host ST2+ Treg prior to allogeneic hematopoietic cell transplantation decreases macrophage and effector T cell activation reducing acute GVHD (2016) (0)
Transitory response to vaccination with PSCA-/PSA-peptide loaded, autologous dendritic cells in patients with metastatic, hormone-refractory prostate cancer (2004) (0)
Cellular and Humoral SARS-CoV-2 Vaccination Responses in 192 Adult Recipients of Allogeneic Hematopoietic Cell Transplantation (2022) (0)
Metabolic Reprogramming Overcomes T Cell Inhibition By AML Cells (2018) (0)
Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT) (2021) (0)
Integrin αV Inhibition Reduces GvHD by Targeting inflammatory Neovascularization (2011) (0)
Tissue Damage and Lymphoma Derived Chemoattractive Signals Impact Regulatory T Cell Trafficking After Allogeneic Hematopoietic Cell Transplantation. (2009) (0)
Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. (2023) (0)
Prostaglandin E2 controls the metabolic adaptation of T cells to the intestinal microenvironment (2023) (0)
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms (2020) (0)
cells T + regulatory T cells compared with conventional CD4 + Foxp3 + CD25 + Differential impact of mammalian target of rapamycin inhibition on CD4 (2008) (0)
Epithelial chimerism in the oral mucosa after human hematopoietic cell transplantation (2005) (0)
tumour cells and hypercoagulability : a lethal relationship in metastatic breast cancer (2016) (0)
Vaccination of Advanced Prostate Cancer Patients with PSCA and PSA Peptide-Loaded Dendritic Cells Induces Cellular Immune Responses That Correlate with Superior Overall Survival. (2005) (0)
Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip (2004) (0)
JAK1/2 Inhibition Suppresses T Cell Proliferation and Inflammatory Cytokine Production In An Allogeneic Setting and Ameliorates Graft-Versus-Host Disease (GvHD) In a Murine GvHD Model (2013) (0)
β 2-Microglobulin - A Trigger for NLRP3 Inflammasome Activation in Tumor-Associated Macrophages Promoting Multiple Myeloma Progression (2021) (0)
Pathophysiology of gastrointestinal acute graft‐versus‐host disease and the potential role of glucagon‐like peptide 2 (2023) (0)
Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function (2020) (0)
Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized, Phase 3 REACH3 Study (2022) (0)
Novel Treatment for Graft-versus-Host Disease (2021) (0)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Is Followed by Epithelial Chimerism of the Oral Mucosal. (2004) (0)
Regulation of Immune Responses during Acute GvHD Via the IL-33/ST2 Axis (2014) (0)
Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT (2019) (0)
XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors. (2008) (0)
Neutrophil Granulocytes Mediate Cellular Communication Between the Damaged Intestinal Tract and Mesenteric Lymph Nodes at the Onset of Intestinal Graft-Versus-Host Disease (2016) (0)
Myelodysplastic Syndrome Caused By Activating Kras Mutation in the Non-Hematopoietic Bone Marrow Microenvironment (2015) (0)
Effect of biglycan on melanoma invasiveness via increased tissue stiffness and integrin-β1 expression. (2016) (0)
MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production. (2023) (0)
AML-142 Patients at High Risk of Relapse Post-Transplant: A Phase 1 Study Design With a Novel Treatment Strategy Using the Estimand Framework. (2022) (0)
Hematopoietic cell transplantation from unrelated and related donors after a fludarabine-alkylator-based regimen is a reasonable treatment option for older patients (>60 years) with active hematologic malignancies (2005) (0)
Immunotherapeutic approaches targeting prostate cancer and its microenvironment (2012) (0)
MiR-155 Regulates Acute GvHD By Reducing NLRP3 Inflammasome Activity Via Targeting SOCS1 In Antigen-Presenting Cells (2013) (0)
Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation (2020) (0)
Allogeneic Hematopoietic Cell Nanoparticle-Labeled Dendritic Cells Tolerogenic Function of Inhibition on Lymphoid Homing and Impact of Mammalian Target of Rapamycin (2008) (0)
Abstract 5093: Bcr-Abl leads to mast cell differentiation and promotes degranulation of cells derived from a chronic myeloid leukemia mouse model in a Gab2 dependent manner (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert Zeiser?

Robert Zeiser is affiliated with the following schools:

University of California, Berkeley
University of Freiburg
Stanford University